59
Views
0
CrossRef citations to date
0
Altmetric
Meeting Highlights

Highlights from The Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis

28 – 30 March, 2007, Porto

&
Pages 1779-1784 | Published online: 09 Aug 2007

Bibliography

  • SEEMAN E: Why do bones break? A reappraisal of mechanisms of bone fragility. Osteoporos. Int. (2007) 18(Suppl. 1):S1-S2.
  • HAENTJENS P, BOONEN S: Excess mortality after hip fracture among postmenopausal women and ageing men: evidence from data searches and life-table analyses for gender-related differences in absolute risk of death after hip fracture. Osteoporos. Int. (2007) 18(Suppl. 1):S5-S6.
  • STRÖM O, BORGSTRÖM F, ZETHRAEUS N, JOHNELL O, JöNSSON B: Long term quality of life related to osteoporotic fractures. 13 – 18 months after fracture. Osteoporos. Int. (2007) 18(Suppl. 1):S6.
  • SZULC P, DELMAS PD: Prevalent falls predict incident non-vertebral fractures in elderly men – prospective minos study. Osteoporos. Int. (2007) 18(Suppl. 1):S5.
  • HADJI P, NICKELSEN T, MARIN F et al.: Bone mineral density response to 2 years of continuous treatment with teriparatide: final results from the eurofors study. Osteoporos. Int. (2007) 18(Suppl. 1):S7.
  • DELMAS PD, SILVERMAN SL, WATTS NB, LANGE JL, LINDSAY R: Risedronate and alendronate for the reduction of nonvertebral fractures, a retrospective cohort study. Osteoporos. Int. (2007) 18(Suppl. 1):S7-S8.
  • FELSENBERG D, MILLER PD, LEWIECKI EM, LIBANATI C, LIU Y, BECK TJ: Hip structural analysis of the proximal femur in postmenopausal women with low bone mass treated with denosumab. Osteoporos. Int. (2007) 18(Suppl. 1):S9.
  • LYNCH NO, EARNSHAW SR, GRAHAM CN, MIDDELHOVEN H: Cost-effectivenss of ibandronate injection iv in the treatment of uk women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Osteoporos. Int. (2007) 18(Suppl. 1):S11-S12.
  • STOCH SA, MILLER DL, VAN DYCK K et al.: Effect of cathepsin k inhibition on bone resorption markers in healthy postmenopausal women. Osteoporos. Int. (2007) 18(Suppl. 1):S8-S9.
  • LIPS P, PFEIFER M, WALLISER J et al.: Treatment effects of vitamin d3 8400 iu once weekly on body sway of elderly subjects with vitamin D insufficiency. Osteoporos. Int. (2007) 18(Suppl. 1):S11.
  • BOONEN S, WARDLAW D, BASTIAN L, LIPS P, VAN MEIRHAEGHE J, CUMMINGS S: International multicenter randomized comparison of balloon kyphoplasty and non-surgical management in patients with acute vertebral body compression fractures. Osteoporos. Int. (2007) 18(Suppl. 1):S10-S11.
  • REGINSTER J-Y, BRIXEN K, CORMIER C, CANNATA J: Strontium ranelate demonstrates vertebral and non-vertebral anti fracture efficacy including hip fractures over 5 years in post menopausal osteoporotic women. Osteoporos. Int. (2007) 18(Suppl. 1):S21.
  • BLACK DM, DELMAS PD, EASTELL R et al.: Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: the horizon pivotal fracture trial. Osteoporos. Int. (2007) 18(Suppl. 1):S21.
  • CHAPURLAT RD, ARLOT M, BURT-PICHAT B et al.: Effect of long-term bisphosphonates on bone turnover and microdamage in osteoporotic women: a bone biopsy study. Osteoporos. Int. (2007) 18(Suppl. 1):S10.
  • JUNG TI, VON DER GABLENTZ J, FELSENBERG D et al.: Osteonecrosis of the jaw under bisphosphonate therapy – a german register for patients with osteonecrosis of the jaw. Osteoporos. Int. (2007) 18(Suppl. 1):S8.
  • DERE W: Are anti-osteoporotic agents the solution for treating osteoarthritis? Osteoporos. Int. (2007) 18(Suppl. 1):S2-S3.
  • ZHAI G, HART DJ, KATO BS, SHARMA L, MACGREGOR A, SPECTOR TD: Genetic contribution to knee radiographic osteoarthritis and knee alignment: a longitudinal twin study. Osteoporos. Int. (2007) 18(Suppl. 1):S12.
  • MARTEL-PELLETIER J, RAYNAULD JP, BERTHIAUME MJ et al.: The loss of cartilage volume/thickness on the weight bearing areas in knee osteoarthritic patients, assessed by quantitative mri, is correlated with severity of symptoms and worsening of pain over time. Osteoporos. Int. (2007) 18(Suppl. 1):S12-S13.
  • BEATTIE KA, DURYEA J, PUI M et al.: The contribution of medial femoral and tibial cartilage thickness to minimum joint space width in osteoarthritic knees. Osteoporos. Int. (2007) 18(Suppl. 1):S13.
  • BEATTIE KA, DURYEA J, PUI M et al.: Minimum joint space width values in healthy individuals and patients with knee OA. Osteoporos. Int. (2007) 18(Suppl. 1):S13-S14.
  • HUELS J, OMAR M, DUBOIS RW, DOAN QV: Lumiracoxib is cost-effective compared with celecoxib and NSAID plus proton pump inhibitor combinations for the management of osteoarthritis among patients with a prior gastrointestinal event in the United Kingdom. Osteoporos. Int. (2007) 18(Suppl. 1):S14.
  • KAHAN A, VIGNON E, UEBELHART D, REGINSTER J-Y: A randomized controlled trial with chondroitin sulfate involving over 600 patients: stopp (study on osteoarthritis progression prevention). Osteoporos. Int. (2007) 18(Suppl. 1):S14-S15.
  • HERRERO-BEAUMONT G, BRANCO J, FOR THE GUIDE INVESTIGATORS. Glucosamine sulfate improves quality of life of knee osteoarthritis patients in the glucosamine unum in die efficacy (GUIDE) trial. Osteoporos. Int. (2007) 18(Suppl. 1):S16.
  • BRUYÈRE O, DELFERRIERE D, ROUX C, FECHTENBAUM J, KOLTA S, REGINSTER J-Y: Strontium ranelate prevents spine osteoarthritis progression in patients with prevalent spinal osteoarthritis. Osteoporos. Int. (2007) 18(Suppl. 1):S16-S17.
  • PELLETIER J-P, RAYNAULD J-P, BIAS P et al.: Licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, reduces the progression of knee osteoarthritis (OA): a double blind, multicenter two-year study using quantitative MRI. Osteoporos. Int. (2007) 18(Suppl. 1):S18.
  • COHEN SB, VALEN P, RITCHLIN C et al.: Inhibition of rankl with denosumab decreases progression of bone erosions in patients with rheumatoid arthritis: MRI results at 6 months. Osteoporos. Int. (2007) 18(Suppl. 1):S15-S16.
  • LANE N, IANNINI M, ATKINS C et al.: Inhibition of RANKL with denosumab reduces markers of bone and cartilage turnover in patients with rheumatoid arthritis. Osteoporos. Int. (2007) 18(Suppl. 1):S17-S18.
  • QUESADA GÓMEZ JM, CORTÉS X, RAMÍREZ E: Adherence to therapeutic recommendation for calcium + vitamin D supplementation in the pharmacologic treatment of postmenopausal osteoporosis in spain: the combicad study. Osteoporos. Int. (2007) 18(Suppl. 1):S19.
  • PIERCY J, BADAMGARAV E, TIMPERS E, TOMPKINS R: Impact of incomplete patient compliance with medication instructions for bisphosphonate therapy on healthcare utilization and quality of life. Osteoporos. Int. (2007) 18(Suppl. 1):S19.
  • RABENDA V, REGINSTER J-Y: Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. (2007) 18(Suppl. 1):S19-S20.
  • DANESE M, BADAMGARAV E, BAUER D: Poor patient adherence to osteoporosis treatment is associated with an increased rate and cost of hip fracture. Osteoporos. Int. (2007) 18(Suppl. 1):S20.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.